These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33663084)

  • 21. High lymphocyte counts before antithymocyte globulin administration predict acute graft-versus-host disease.
    Shiratori S; Ohigashi H; Ara T; Yasumoto A; Goto H; Nakagawa M; Sugita J; Onozawa M; Kahata K; Endo T; Hashimoto D; Teshima T
    Ann Hematol; 2021 May; 100(5):1321-1328. PubMed ID: 33215225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).
    Bacigalupo A; Lamparelli T; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Barbanti M; Sacchi N; Van Lint MT; Bosi A
    Blood; 2001 Nov; 98(10):2942-7. PubMed ID: 11698275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
    Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation.
    Miyao K; Kuwatsuka Y; Murata M; Nagafuji K; Teshima T; Takeuchi Y; Shiratori S; Najima Y; Uchida N; Tanaka M; Sawa M; Ota S; Fukuda T; Ozawa Y; Kako S; Kawakita T; Ara T; Tanaka J; Kanda Y; Atsuta Y; Kanda J; Terakura S;
    Transplant Cell Ther; 2022 Mar; 28(3):153.e1-153.e11. PubMed ID: 34954151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.
    Chang YJ; Wang Y; Mo XD; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Chen Y; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Cancer; 2017 Aug; 123(15):2881-2892. PubMed ID: 28301690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haploidentical donor stem cell transplantation had a lower incidence of bronchiolitis obliterans syndrome compared with HLA-matched sibling donor transplantation in patients with hematologic malignancies: Benefit from ATG?
    Weng G; Fan Z; Xue H; Huang F; Xu N; Jin H; Yu S; Ye Z; Fan J; Xuan L; Liu Q
    Front Immunol; 2022; 13():1036403. PubMed ID: 36389692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy analysis of anti-thymocyte globulin regimens with different timing strategies for matched sibling donor hematopoietic stem cell transplantation].
    Du JS; Wang HT; Dou LP; Wang N; Li F; Jin XS; Liu DH
    Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):660-666. PubMed ID: 37803840
    [No Abstract]   [Full Text] [Related]  

  • 28. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor.
    Cho BS; Min GJ; Park SS; Yoon SY; Park S; Jeon YW; Shin SH; Yahng SA; Yoon JH; Lee SE; Eom KS; Kim YJ; Min CK; Cho SG; Kim DW; Lee JW; Kim HJ; Lee S
    Am J Hematol; 2021 Nov; 96(11):1441-1449. PubMed ID: 34390504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
    Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
    Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Battipaglia G; Labopin M; Hamladji RM; Blaise D; Chevallier P; Brissot E; Gerbitz A; Socié G; Afanasyev B; Ciceri F; Meijer E; Koc Y; Cornelissen JJ; Huynh A; Ozdogu H; Maertens J; Paul F; Labussière-Wallet H; Ruggeri A; Aljurf M; Bazarbachi A; Savani B; Nagler A; Mohty M
    Cancer; 2021 Jan; 127(2):209-218. PubMed ID: 33119152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Similar incidence of severe acute GVHD and less severe chronic GVHD in PBSCT from unmanipulated, haploidentical donors compared with that from matched sibling donors for patients with haematological malignancies.
    Li HH; Li F; Gao CJ; Huang WR; Bo J; Dou LP; Wang LL; Jing Y; Wang L; Li WJ; Yu L; Liu DH
    Br J Haematol; 2017 Jan; 176(1):92-100. PubMed ID: 27714774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
    Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N
    Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
    Hamadani M; Blum W; Phillips G; Elder P; Andritsos L; Hofmeister C; O'Donnell L; Klisovic R; Penza S; Garzon R; Krugh D; Lin T; Bechtel T; Benson DM; Byrd JC; Marcucci G; Devine SM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1422-30. PubMed ID: 19822302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
    Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Graft-Versus-Host Disease Prophylaxis Using Low-Dose Antithymocyte Globulin in Peripheral Blood Stem Cell Transplantation-A Matched-Pair Analysis.
    Shiratori S; Kurata M; Sugita J; Ota S; Kasahara S; Ishikawa J; Imada K; Onishi Y; Ishiyama K; Ashida T; Kanda Y; Ichinohe T; Fukuda T; Atsuta Y; Teshima T
    Transplant Cell Ther; 2021 Dec; 27(12):995.e1-995.e6. PubMed ID: 34500126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies.
    Messina G; Giaccone L; Festuccia M; Irrera G; Scortechini I; Sorasio R; Gigli F; Passera R; Cavattoni I; Filippi AR; Schianca FC; Pini M; Risitano AM; Selleri C; Levis A; Mordini N; Gallamini A; Pastano R; Casini M; Aglietta M; Montanari M; Console G; Boccadoro M; Ricardi U; Bruno B;
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1600-7. PubMed ID: 22484666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
    Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bondarenko SN; Afanasyev BV
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1037-1042. PubMed ID: 26970381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors.
    Shiratori S; Sugita J; Fuji S; Aoki J; Sawa M; Ozawa Y; Hashimoto D; Matsuoka KI; Imada K; Doki N; Ashida T; Ueda Y; Tanaka M; Sawayama Y; Ichinohe T; Terakura S; Morishima S; Atsuta Y; Fukuda T; Teshima T
    Bone Marrow Transplant; 2021 Sep; 56(9):2231-2240. PubMed ID: 33963304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation.
    Devillier R; Labopin M; Chevallier P; Ledoux MP; Socié G; Huynh A; Bourhis JH; Cahn JY; Roth-Guepin G; Mufti G; Desmier D; Michallet M; Fegueux N; Ciceri F; Baron F; Blaise D; Nagler A; Mohty M
    Bone Marrow Transplant; 2018 Apr; 53(4):431-437. PubMed ID: 29330391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.